Quick Answer
Neumora Therapeutics, Inc. reported Net Income of -$236.93 million for fiscal year 2025.
Neumora Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$236.93M | +2.8% |
| 2024 | -$243.79M | -3.3% |
| 2023 | -$235.93M | -80.2% |
| 2022 | -$130.90M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$56.76M | +21.8% | -7.6% |
| June 30, 2025 | -$52.73M | +10.2% | +22.4% |
| March 31, 2025 | -$67.99M | -26.6% | +6.3% |
| September 30, 2024 | -$72.55M | -36.8% | -23.6% |
| June 30, 2024 | -$58.70M | -52.3% | -9.3% |
| March 31, 2024 | -$53.72M | -50.8% | -1.3% |
| September 30, 2023 | -$53.03M | -80.7% | -37.6% |
| June 30, 2023 | -$38.54M | -26.9% | -8.2% |
- Neumora Therapeutics, Inc. showed an increase of +2.8% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s net income has declined by 81.0% (from -$130.90 million to -$236.93 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: